PMID- 32350356
OWN - NLM
STAT- MEDLINE
DCOM- 20201124
LR  - 20210429
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Apr 29
TI  - Identifying the HLA DRB1-DQB1 molecules and predicting epitopes associated with 
      high-risk HPV infection clearance and redetection.
PG  - 7306
LID - 10.1038/s41598-020-64268-x [doi]
LID - 7306
AB  - Several determining factors are involved in HPV infection outcomes; human 
      leukocyte antigen (HLA) polymorphisms have been described as related factors. 
      This study has ascertained the effect of genetic variation on HLA-DRB1 and DQB1 
      genes on HPV-16/-18/-31/-33/-45 and -58 clearance and redetection in Colombian 
      women. PCR and qPCR were used for viral identification and the Illumina MiSeq 
      system was used for HLA-typing of cervical samples (n = 276). Survival models 
      were adjusted for identifying alleles/haplotypes related to HPV 
      clearance/redetection; L1/L2 protein-epitope binding to MHC-II molecules was also 
      predicted. Significant associations suggested effects favouring or hampering 
      clearance/redetection events depending on the viral type involved in infection, 
      e.g. just DRB1*12:01:01G favoured HPV-16 (coeff: 4.8) and HPV-45 clearance 
      (coeff: 12.65) whilst HPV-18 (coeff: 2E-15), HPV-31 (coeff: 8E-17) and HPV-58 
      hindered elimination (coeff: 1E-14). An effect was only observed for some alelles 
      when configured as haplotypes, e.g. DRB1*04:07:01G (having the greatest frequency 
      in the target population) was associated with DQB1*02:01:1G or *03:02:03. Epitope 
      prediction identified 23 clearance-related peptides and 29 were 
      redetection-related; eight might have been related to HPV-16/-18 and -58 
      persistence and one to HPV-18 elimination. HLA allele/haplotype relationship with 
      the course of HPV infection (clearance/redetection) depended on the infecting HPV 
      type, in line with the specific viral epitopes displayed.
FAU - Del Rio-Ospina, Luisa
AU  - Del Rio-Ospina L
AD  - Molecular Biology and Immunology Department, Fundacion Instituto de Inmunologia 
      de Colombia, Carrera 50 # 26-20, Bogota, Colombia.
AD  - Clinical Research Group, Instituto Nacional de Cancerologia, Calle 1 # 9-85, 
      Bogota, Colombia.
FAU - Camargo, Milena
AU  - Camargo M
AD  - Molecular Biology and Immunology Department, Fundacion Instituto de Inmunologia 
      de Colombia, Carrera 50 # 26-20, Bogota, Colombia.
AD  - PhD Programme in Biomedical and Biological Sciences, Universidad del Rosario, 
      Carrera 24 # 63C-69, Bogota, Colombia.
AD  - Animal Science Faculty, Universidad de Ciencias Aplicadas y Ambientales 
      (U.D.C.A), Calle 222 # 55-37, Bogota, Colombia.
FAU - Soto-De Leon, Sara C
AU  - Soto-De Leon SC
AD  - Molecular Biology and Immunology Department, Fundacion Instituto de Inmunologia 
      de Colombia, Carrera 50 # 26-20, Bogota, Colombia.
FAU - Sanchez, Ricardo
AU  - Sanchez R
AD  - Faculty of Medicine, Universidad Nacional de Colombia, Carrera 45 # 26-85, 
      Bogota, Colombia.
FAU - Moreno-Perez, Darwin A
AU  - Moreno-Perez DA
AD  - Molecular Biology and Immunology Department, Fundacion Instituto de Inmunologia 
      de Colombia, Carrera 50 # 26-20, Bogota, Colombia.
AD  - School of Medicine and Health Sciences, Universidad del Rosario, Carrera 24 # 
      63C-69, Bogota, Colombia.
FAU - Patarroyo, Manuel E
AU  - Patarroyo ME
AD  - Molecular Biology and Immunology Department, Fundacion Instituto de Inmunologia 
      de Colombia, Carrera 50 # 26-20, Bogota, Colombia.
AD  - Faculty of Medicine, Universidad Nacional de Colombia, Carrera 45 # 26-85, 
      Bogota, Colombia.
FAU - Patarroyo, Manuel A
AU  - Patarroyo MA
AD  - Molecular Biology and Immunology Department, Fundacion Instituto de Inmunologia 
      de Colombia, Carrera 50 # 26-20, Bogota, Colombia. mapatarr.fidic@gmail.com.
AD  - School of Medicine and Health Sciences, Universidad del Rosario, Carrera 24 # 
      63C-69, Bogota, Colombia. mapatarr.fidic@gmail.com.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200429
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Epitopes)
RN  - 0 (HLA-DQ beta-Chains)
RN  - 0 (HLA-DQB1 antigen)
RN  - 0 (HLA-DRB1 Chains)
SB  - IM
MH  - Adult
MH  - *Alleles
MH  - *Alphapapillomavirus/genetics/immunology
MH  - Disease-Free Survival
MH  - *Epitopes/genetics/immunology
MH  - Female
MH  - Follow-Up Studies
MH  - *HLA-DQ beta-Chains/genetics/immunology
MH  - *HLA-DRB1 Chains/genetics/immunology
MH  - *Haplotypes
MH  - Humans
MH  - Middle Aged
MH  - *Papillomavirus Infections/genetics/immunology/mortality
MH  - Survival Rate
PMC - PMC7190668
COIS- The authors declare no competing interests.
EDAT- 2020/05/01 06:00
MHDA- 2020/11/25 06:00
PMCR- 2020/04/29
CRDT- 2020/05/01 06:00
PHST- 2019/11/14 00:00 [received]
PHST- 2020/03/25 00:00 [accepted]
PHST- 2020/05/01 06:00 [entrez]
PHST- 2020/05/01 06:00 [pubmed]
PHST- 2020/11/25 06:00 [medline]
PHST- 2020/04/29 00:00 [pmc-release]
AID - 10.1038/s41598-020-64268-x [pii]
AID - 64268 [pii]
AID - 10.1038/s41598-020-64268-x [doi]
PST - epublish
SO  - Sci Rep. 2020 Apr 29;10(1):7306. doi: 10.1038/s41598-020-64268-x.